title: [Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded access program].
abstract: BACKGROUND
  Efavirenz (EFV) is one of the latest antiretroviral compounds appeared in the market. Its toxicity profile is not well known.
  
  
  METHODS
  The rate of adverse events was examined in 250 subjects enrolled in the expanded access program in a single institution located in Madrid, Spain.
  
  
  RESULTS
  Adverse events grade >= 2 (WHO) were recorded in 33 (13.2%) persons. The most common were neuropsychiatric disorders (8.4%), cutaneous lesions (3.2%), and gastrointestinal problems (0.8%). The drug needed to be discontinued in 17 (6.8%) patients.
  
  
  CONCLUSIONS
  The rate of adverse events grade moderate-to-severe in patients receiving EFV is relatively low (13. 4%), without evidence of cross-toxicity (i.e., rash by nevirapine). Neuropsychiatric and dermatological conditions are the most common, and ten to resolve spontaneously in two
authors.affiliation: Servicios de Enfermedades Infecciosas y aFarmacia. Hospital Carlos III. Instituto de Salud Carlos III. Madrid.
authors.forename: C
authors.initials: C
authors.lastname: Dona
authors.forename: V
authors.initials: V
authors.lastname: Soriano
authors.forename: P
authors.initials: P
authors.lastname: Barreiro
authors.forename: I
authors.initials: I
authors.lastname: Jiménez-Náchera
authors.forename: J
authors.initials: J
authors.lastname: González-Lahoz
mesh_terms: D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects*; D048588:Benzoxazines; D003521:Cyclopropanes; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010078:Oxazines / Q000009:adverse effects*
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; C098320:efavirenz